Partnership enables Moderna to leverage Caris'
vast library of de-identified, multi-modal data and analytics
capabilities to accelerate precision medicine and the delivery of
novel medicines to patients
IRVING,
Texas, Oct. 24, 2023 /PRNewswire/ -- Caris
Life Sciences®(Caris), the leading next-generation AI
TechBio company and precision medicine pioneer that is actively
developing and delivering innovative solutions to revolutionize
healthcare and improve the human condition using molecular science
and AI, today announced a new agreement with Moderna (NASDAQ:MRNA)
in support of Moderna's oncology and novel therapeutics
initiatives.
Caris Life Sciences and Moderna
Announce Multi-Year Strategic Partnership to Advance mRNA-Based
Oncology Therapeutics
Through this multi-year agreement, Moderna will leverage Caris'
vast library of de-identified, multi-modal data solutions derived
from whole exome sequencing, whole transcriptome sequencing and
protein analyses along with claims data to enhance development
strategies for Moderna's oncology pipeline, including facilitation
of optimal clinical trial design, discovery of novel biomarkers and
characterization of resistance mechanisms.
"Partnering with Caris Life Sciences will support Moderna's
oncology portfolio with clinico-genomics data from Caris'
industry-leading and comprehensive suite of integrated precision
medicine capabilities," stated Praveen Aanur, MD, MPH, MBA, Vice
President, Oncology Therapeutic Area Head of Moderna.
"We are thrilled to partner with Moderna to impact and advance
the field of cancer treatment with mRNA medicines, with a common
goal of improving patient lives," said David Spetzler, MS, PhD, MBA, President of Caris
Life Sciences. "The aggregate strength of our combined molecular,
data science and therapeutics technologies will support the
predictive modeling of patient responses to therapies, and more
generally, may help improve the probability of technical and
regulatory success of Moderna's innovative medicines."
As the pioneer in precision medicine and molecular profiling,
Caris has created the largest clinico-genomic database coupled with
cognitive computing to unravel the molecular complexity of disease.
Caris was the first in the industry to provide Whole Exome
Sequencing DNA coverage and Whole Transcriptome Sequencing RNA
coverage (WES / WTS) for every patient.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading
next-generation AI TechBio company and precision medicine pioneer
that is actively developing and delivering innovative solutions to
revolutionize healthcare and improve the human condition
using molecular science and AI. Through comprehensive
molecular profiling (Whole Exome and Whole Transcriptome
Sequencing) and the application of advanced AI and machine learning
algorithms, Caris has created the large-scale, clinico-genomic
database and computing capability needed to analyze and unravel the
molecular complexity of disease. This convergence of sequencing
power, big data and AI technologies provides an unmatched platform
to deliver the next-generation of precision medicine tools for
early detection, diagnosis, monitoring, therapy selection and drug
development.
Headquartered in Irving, Texas,
Caris has offices in Phoenix, New
York, Tokyo, Japan and
Basel, Switzerland. Caris or its
distributor partners provide services in the U.S., Europe, Asia
and other international markets. To learn more, please visit
CarisLifeSciences.com.
About Moderna
In over 10 years since its inception, Moderna has transformed from
a research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across seven modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for rapid clinical and commercial production at
scale. Moderna maintains alliances with a broad range of domestic
and overseas government and commercial collaborators, which has
allowed for the pursuit of both groundbreaking science and rapid
scaling of manufacturing. Most recently, Moderna's capabilities
have come together to allow the authorized use and approval of one
of the earliest and most effective vaccines against the COVID-19
pandemic.
Moderna's mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Moderna has been named a top
biopharmaceutical employer by Science for the past eight
years. To learn more, visit www.modernatx.com.
Moderna Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including statements regarding: the potential for Moderna
to launch up to 15 products in the next five years, and advancement
of new products into clinical studies; Moderna's discussions with
regulators and the potential for accelerated, conditional or other
product approvals in certain markets; the expectation that INT will
begin a Phase 3 study in NSCLC in 2023; clinical trial progress and
results from Moderna's programs; Moderna's ability to develop
combination vaccines and the benefits of those vaccines; the
ability of Moderna's XBB.1.5 monovalent COVID-19 vaccine
(mRNA-1283.815) to provide protection during the fall 2023/2024
season; Moderna's ability to develop updated vaccines to provide
protection against evolving SARS-CoV-2 variants of concern; the
safety and tolerability profile for Moderna's products; and the
size of the addressable markets being targeted by Moderna's
pipeline, Moderna's estimated future revenue from sales in those
markets and its anticipated future margins. The forward-looking
statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties, and other factors, many of which are beyond
Moderna's control and which could cause actual results to differ
materially from those expressed or implied by these forward-looking
statements. These risks, uncertainties, and other factors include,
among others, those risks and uncertainties described under the
heading "Risk Factors" in Moderna's Annual Report on Form 10-K for
the fiscal year ended December 31,
2022, filed with the U.S. Securities and Exchange Commission
(SEC), and in subsequent filings made by Moderna with the SEC,
which are available on the SEC's website at www.sec.gov.
Except as required by law, Moderna disclaims any intention or
responsibility for updating or revising any forward-looking
statements contained in this press release in the event of new
information, future developments or otherwise. These
forward-looking statements are based on Moderna's current
expectations and speak only as of the date of this press
release.
Caris Life Sciences Media Contact:
Lisa Burgner
corpcomm@CarisLS.com
214.294.5606
Caris Life Sciences Business Development
Contact:
Brian Lamon, Ph.D.
Chief Business Officer, Head of BioPharma Business
Development
blamon@CarisLS.com
609.955.8883
Moderna Media Contact:
Chris
Ridley
Vice President, Communications
617.800.3651
Chris.Ridley@modernatx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-and-moderna-announce-multi-year-strategic-partnership-to-advance-mrna-based-oncology-therapeutics-301965307.html
SOURCE Caris Life Sciences